Literature DB >> 20011465

Estimating the size of treatment effects: moving beyond p values.

James J McGough1, Stephen V Faraone.   

Abstract

OBJECTIVE: To increase understanding of effect size calculations among clinicians who over-rely on interpretations of P values in their assessment of the medical literature.
DESIGN: We review five methods of calculating effect sizes: Cohen's d (also known as the standardized mean difference)-used in studies that report efficacy in terms of a continuous measurement and calculated from two mean values and their standard deviations; relative risk-the ratio of patients responding to treatment divided by the ratio of patients responding to a different treatment (or placebo), which is particularly useful in prospective clinical trials to assess differences between treatments; odds ratio- used to interpret results of retrospective case-control studies and provide estimates of the risk of side effects by comparing the probability (odds) of an outcome occurring in the presence or absence of a specified condition; number needed to treat-the number of subjects one would expect to treat with agent A to have one more success (or one less failure) than if the same number were treated with agent B; and area under the curve (also known as the drug-placebo response curve)-a six-step process that can be used to assess the effects of medication on both worsening and improvement and the probability that a medication-treated subject will have a better outcome than a placebo-treated subject.
CONCLUSION: Effect size statistics provide a better estimate of treatment effects than P values alone.

Entities:  

Keywords:  Effect sizes; clinical trials; comparing treatment outcomes; pediatric psychopharmacology

Year:  2009        PMID: 20011465      PMCID: PMC2791668     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  32 in total

1.  A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder.

Authors:  S R Pliszka; R G Browne; R L Olvera; S K Wynne
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-05       Impact factor: 8.829

2.  Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults.

Authors:  S Kuperman; P J Perry; G R Gaffney; B C Lund; K A Bever-Stille; S Arndt; T L Holman; D J Moser; J S Paulsen
Journal:  Ann Clin Psychiatry       Date:  2001-09       Impact factor: 1.567

3.  Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study.

Authors:  Timothy E Wilens; Barbara R Haight; Joseph P Horrigan; James J Hudziak; Norman E Rosenthal; Daniel F Connor; Kenneth D Hampton; Nathalie E Richard; Jack G Modell
Journal:  Biol Psychiatry       Date:  2005-04-01       Impact factor: 13.382

4.  Treatment for Adolescents with Depression Study (TADS): safety results.

Authors:  Graham Emslie; Christopher Kratochvil; Benedetto Vitiello; Susan Silva; Taryn Mayes; Steven McNulty; Elizabeth Weller; Bruce Waslick; Charles Casat; John Walkup; Sanjeev Pathak; Paul Rohde; Kelly Posner; John March
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2006-12       Impact factor: 8.829

5.  Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.

Authors:  M L Wolraich; L L Greenhill; W Pelham; J Swanson; T Wilens; D Palumbo; M Atkins; K McBurnett; O Bukstein; G August
Journal:  Pediatrics       Date:  2001-10       Impact factor: 7.124

6.  A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder.

Authors:  Laurence L Greenhill; Robert L Findling; James M Swanson
Journal:  Pediatrics       Date:  2002-03       Impact factor: 7.124

7.  Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder.

Authors:  Joseph Biederman; Declan Quinn; Margaret Weiss; Sabri Markabi; Meredith Weidenman; Kathryn Edson; Goeril Karlsson; Harald Pohlmann; Sharon Wigal
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

8.  A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.

Authors:  James J McGough; Sharon B Wigal; Howard Abikoff; John M Turnbow; Kelly Posner; Eliot Moon
Journal:  J Atten Disord       Date:  2006-02       Impact factor: 3.256

9.  Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.

Authors:  David Michelson; Lenard Adler; Thomas Spencer; Frederick W Reimherr; Scott A West; Albert J Allen; Douglas Kelsey; Joachim Wernicke; Anthony Dietrich; Denái Milton
Journal:  Biol Psychiatry       Date:  2003-01-15       Impact factor: 13.382

10.  A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents.

Authors:  Paula D Riggs; Shannon K Hall; Susan K Mikulich-Gilbertson; Michelle Lohman; Ashley Kayser
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2004-04       Impact factor: 8.829

View more
  79 in total

Review 1.  Suicidality and posttraumatic stress disorder (PTSD) in adolescents: a systematic review and meta-analysis.

Authors:  Maria Panagioti; Patricia A Gooding; Kalliopi Triantafyllou; Nicholas Tarrier
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-11-15       Impact factor: 4.328

2.  Lower Extremity Biomechanics During a Drop-Vertical Jump and Muscle Strength in Women With Patellofemoral Pain.

Authors:  Andrea Baellow; Neal R Glaviano; Jay Hertel; Susan A Saliba
Journal:  J Athl Train       Date:  2020-06-23       Impact factor: 2.860

3.  Comparison of rectal and aural core body temperature thermometry in hyperthermic, exercising individuals: a meta-analysis.

Authors:  Robert Huggins; Neal Glaviano; Naoki Negishi; Douglas J Casa; Jay Hertel
Journal:  J Athl Train       Date:  2012 May-Jun       Impact factor: 2.860

4.  Comparing brief interventions for suicidal individuals not engaged in treatment: A randomized clinical trial.

Authors:  Erin F Ward-Ciesielski; Julia A Tidik; Amanda J Edwards; Marsha M Linehan
Journal:  J Affect Disord       Date:  2017-07-06       Impact factor: 4.839

Review 5.  How to assess the clinical impact of treatments on patients, rather than the statistical impact of treatments on measures.

Authors:  Helena Chmura Kraemer; Ellen Frank; David J Kupfer
Journal:  Int J Methods Psychiatr Res       Date:  2011-06       Impact factor: 4.035

6.  A META-ANALYSIS OF COGNITIVE BEHAVIOR THERAPY AND MEDICATION FOR CHILD OBSESSIVE-COMPULSIVE DISORDER: MODERATORS OF TREATMENT EFFICACY, RESPONSE, AND REMISSION.

Authors:  Joseph F McGuire; John Piacentini; Adam B Lewin; Erin A Brennan; Tanya K Murphy; Eric A Storch
Journal:  Depress Anxiety       Date:  2015-06-30       Impact factor: 6.505

Review 7.  Statins and their effect on cognition: Let's clear up the confusion.

Authors:  Jérémie M Gauthier; Anne Massicotte
Journal:  Can Pharm J (Ott)       Date:  2015-05

Review 8.  A systematic review and meta-analysis of mobile devices and weight loss with an intervention content analysis.

Authors:  Lynnette Nathalie Lyzwinski
Journal:  J Pers Med       Date:  2014-06-30

Review 9.  Parent-based adolescent sexual health interventions and effect on communication outcomes: a systematic review and meta-analyses.

Authors:  Diane Santa Maria; Christine Markham; Shirley Bluethmann; Patricia Dolan Mullen
Journal:  Perspect Sex Reprod Health       Date:  2015-01-30

Review 10.  Comparative efficacy of parathyroidectomy and active surveillance in patients with mild primary hyperparathyroidism: a systematic review and meta-analysis.

Authors:  N Singh Ospina; S Maraka; R Rodriguez-Gutierrez; A E Espinosa de Ycaza; S Jasim; M Gionfriddo; A Castaneda-Guarderas; J P Brito; A Al Nofal; P Erwin; R Wermers; V Montori
Journal:  Osteoporos Int       Date:  2016-08-25       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.